Dr. Goodman is a psychiatrist and scientist entrepreneur. Dr. Goodman was co-founder and CEO of PsychoGenics, a leading preclinical neuropharmacology company that combines its in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics to evaluate drug candidates for utility across the spectrum of neuropsychiatric disease indications. Using its unique technology platform, PsychoGenics identifies new therapeutic potentials for novel, discontinued and early stage compounds. Dr. Goodman was also co-founder and President of Resolvyx Pharmaceuticals, a biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases. Dr. Goodman's ongoing research interests span a broad spectrum, from the design and development of novel small molecule compounds for neuropsychiatric and inflammatory diseases to the repurposing of existing drugs for new neuropsychiatric indications. In addition to his scientific interests, Dr. Goodman is a practicing physician with a private psychiatry and psychopharmacology practice in New York and Greenwich, CT, where he treats patients with cognitive, mood, and anxiety disorders. Dr. Goodman also maintains an academic appointment as a clinical assistant professor in the Psychiatry Department at Cornell University Medical College, where he teaches medical students, residents and fellows.
He is a graduate of Yale College, Cambridge University, which he attended as a Churchill Fellow, Harvard Medical School, and Columbia Business School.
How do I contact Daniel Wintner Goodman?
The corporate mailing address for Mr. Goodman and other Tonix Pharmaceuticals executives is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. Tonix Pharmaceuticals can also be reached via phone at (862) 799-8599 and via email at investor.relations@tonixpharma.com. Learn More on Daniel Wintner Goodman's contact information.
Has Daniel Wintner Goodman been buying or selling shares of Tonix Pharmaceuticals?
Daniel Wintner Goodman has not been actively trading shares of Tonix Pharmaceuticals in the last ninety days. Most recently, on Tuesday, May 25th, Daniel Wintner Goodman bought 0 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $22,400.00 per share, with a total value of $0.00. Learn More on Daniel Wintner Goodman's trading history.
Who are Tonix Pharmaceuticals' active insiders?
